Tag: price

In this 2025 forecast update, Wealth Megatrends, in collaboration with Weiss Ratings, offers unique insights into gold's continued upward trajectory. The release outlines Sean Brodrick's updated projection of $6,900 gold, framed within rising central bank demand, ongoing monetary volatility, and long-term shifts in asset preservation behavior. This analysis offers a distinct perspective on how this cycle compares to prior periods of financial instability and why mining equities are again drawing interest as part of a broader conversation on gold's role in today's evolving macroeconomic environment.

TEL AVIV, Israel, July 03, 2025 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (“REE” or the “Company”) (Nasdaq: REE), an automotive technology company that develops software-defined vehicle (SDV) technology solutions, today reported that the Company received a letter (the “Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is currently not in compliance with Nasdaq Rule 5450(a)(1). In particular, the Letter stated that the Company’s closing bid price for its Class A ordinary shares (the “Ordinary Shares”) has been below $1.00 per share for the last 30 consecutive business days beginning on May 15, 2025 through June 27, 2025.

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on July 2, 2025 the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share of $1.12, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 2, 2025, the options grant date, and (ii) restricted stock units (RSUs) representing 37,900 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the Company through each vesting date. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

FREMONT, Calif, July 03, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants.

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

In this 2025 strategic update, Safe Money Report outlines a six-step framework for navigating financial instability during what Martin Weiss calls the “Age of Chaos.” With decades of historical data behind its Weiss Ratings system, the firm presents a non-promotional roadmap for evaluating liquidity, asset safety, inflation hedges, and emerging market trends in crypto and real estate. The release examines current economic conditions and how informed analysis, rather than emotion, can inform long-term wealth protection strategies.

Transaction in Own Shares

SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”

The global robotic surgery market size is calculated at USD 13.79 billion in 2025 and is expected to reach around USD 54.66 billion by 2034, growing at a CAGR of 16.54% for the forecasted period.

SURREY, British Columbia, July 03, 2025 (GLOBE NEWSWIRE) -- Economic uncertainty continued to be the main driver in buying decisions as home sales in the Fraser Valley remain mostly unchanged, despite abundant inventory and lower prices.